Back to Authors

Noack, Thilo

https://orcid.org/0000-0003-0245-0147

Mayo Clinic

Leipzig Heart Institute

Citations 5

Effect of Patient-Reported Preprocedural Physical and Mental Health on 10-Year Mortality After Percutaneous or Surgical Coronary Revascularization
Ono, Masafumi , Serruys, Patrick W. , Garg, Scot , Kawashima, Hideyuki , Gao, Chao , Hara, Hironori , Lunardi, Mattia , O’Leary, Neil , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Thuijs, Daniel J.F.M. , Mohr, Friedrich W., Davierwala, Piroze , Spertus, John A. , Onuma, Yoshinobu , Investigators, for the SYNTAX Extended Survival, Piek, Jan J , Mack, Michael J , Holmes, David R , Thuijs, Daniel J F M , Spertus, John A , Cohen, David Jonathan , Onuma, Yoshinobu , Serruys, Patrick W , Garg, Scot , Wang, Rutao , Wykrzykowska, Joanna J. , Kappetein, A. Pieter , Noack, Thilo , Investigators, for the SYNTAX Extended Survival

Circulation | October 24, 2022 | Volume: 146 | Issue: 17 | Pages: 1268-1280

10.1161/circulationaha.121.057021 Get It

Background: Clinical and anatomical characteristics are often considered key factors in deciding between percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with complex coronary artery disease (CAD) such as left-main CAD or 3-vessel disease. However, little is known about the interaction between self-reported preprocedural physical/mental health and clinical outcomes after revascularization. Methods: This subgroup analysis of the SYNTAXES trial (SYNTAX Extended Survival), which is the extended follow-up of the randomized SYNTAX trial (Synergy Between PCI With Taxus and Cardiac Surgery) comparing PCI with CABG in patients with left-main CAD or 3-vessel disease, stratified patients by terciles of Physical (PCS) or Mental Component Summary (MCS) scores derived from the preprocedural 36-Item Short Form Health Survey, with higher PCS and MCS scores representing better physical and mental health, respectively. The primary end point was all-cause death at 10 years. Results: A total of 1656 patients with preprocedural 36-Item Short Form Health Survey data were included in the present study. Both higher PCS and MCS were independently associated with lower 10-year mortality (10-point increase in PCS adjusted hazard ratio, 0.84 [95% CI, 0.73–0.97]; P =0.021; in MCS adjusted hazard ratio, 0.85 [95% CI, 0.76–0.95]; P =0.005). A significant survival benefit with CABG over PCI was observed in the highest PCS (>45.5) and MCS (>52.3) terciles with significant treatment-by-subgroup interactions (PCS P interaction =0.033, MCS P interaction =0.015). In patients with both high PCS (>45.5) and MCS (>52.3), 10-year mortality was significantly higher with PCI compared with CABG (30.5% versus 12.2%; hazard ratio, 2.87 [95% CI, 1.55–5.30]; P =0.001), whereas among those with low PCS (≤45.5) or low MCS (≤52.3), there were no significant differences in 10-year mortality between PCI and CABG, resulting in a significant treatment-by-subgroup interaction ( P interaction =0.002). Conclusions: Among patients with left-main CAD or 3-vessel disease, patient-reported preprocedural physical and mental health status was strongly associated with long-term mortality and modified the relative treatment effects of PCI versus CABG. Patients with the best physical and mental health had better 10-year survival with CABG compared with PCI. Assessment of self-reported physical and mental health is important when selecting the optimal revascularization strategy. Registration: URL: https://www.clinicaltrials.gov ; SYNTAXES Unique identifier: NCT03417050. URL: https://www.clinicaltrials.gov ; SYNTAX Unique identifier: NCT00114972.
Impact of residual angina on long-term clinical outcomes after percutaneous coronary intervention or coronary artery bypass graft for complex coronary artery disease
Ono, Masafumi , Serruys, Patrick W. , Kawashima, Hideyuki , Lunardi, Mattia , Wang, Rutao , Hara, Hironori , Gao, Chao , Garg, Scot , O’Leary, Neil , Holmes, David R. , Morice, Marie‐Claude, Davierwala, Piroze , Onuma, Yoshinobu , Investigators, for the SYNTAX Extended Survival, Head, Stuart J., Mohr, Friedrich‐Wilhelm, Mack, Michael J. , Cohen, David Jonathan , Serruys, Patrick W , Garg, Scot , Onuma, Yoshinobu , Wykrzykowska, Joanna J. , Piek, Jan J , Kappetein, A. Pieter , Noack, Thilo , Spertus, John A. , Investigators, for the SYNTAX Extended Survival

European Heart Journal - Quality of Care and Clinical Outcomes | August 24, 2022 | Volume: 9 | Issue: 5 | Pages: 490-501

10.1093/ehjqcco/qcac052 Get It

Abstract Aims The aim of this study was to investigate the impact on 10-year survival of patient-reported anginal status at 1 year following percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) in patients with left main coronary artery disease (LMCAD) and/or three-vessel CAD (3VD). Methods and results In this post hoc analysis of the randomized SYNTAX Extended Survival study, patients were classified as having residual angina (RA) if their self-reported Seattle Angina Questionnaire angina frequency (SAQ-AF) scale was ≤90 at the 1-year follow-up post-revascularization with PCI or CABG. The primary endpoint of all-cause death at 10 years was compared between the RA and no-RA groups. A sensitivity analysis was performed using a 6-month SAQ-AF. At 1 year, 373 (26.1%) out of 1428 patients reported RA. Whilst RA at 1 year was an independent correlate of repeat revascularization at 5 years [18.3 vs. 11.5%; adjusted hazard ratio (HR): 1.54; 95% confidence interval (CI): 1.10–2.15], it was not associated with all-cause death at 10 years (22.1 vs. 21.6%; adjusted HR: 1.11; 95% CI: 0.83–1.47). These results were consistent when stratified by the modality of revascularization (PCI or CABG) or by anginal frequency. The sensitivity analysis replicating the analyses based on 6-month angina status resulted in similar findings. Conclusion Among patients with LMCAD and/or 3VD, patient-reported RA at 1 year post-revascularization was independently associated with repeat revascularization at 5 years; however, it did not significantly increase 10-year mortality, irrespective of the primary modality of revascularization or severity of RA.
Mortality after multivessel revascularisation involving the proximal left anterior descending artery
Ono, Masafumi , Hara, Hironori , Gao, Chao , Kawashima, Hideyuki , Wang, Rutao , O’Leary, Neil , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Head, Stuart J., Davierwala, Piroze , Mohr, Friedrich W., Garg, Scot , Onuma, Yoshinobu , Bochenek, Andrzej , Escaned, Javier , Curzen, Nick , Garg, Scot , Serruys, Patrick W , Curzen, Nick , Onuma, Yoshinobu , Escaned, Javier , Wykrzykowska, Joanna J. , Piek, Jan J , Kappetein, A. Pieter , Noack, Thilo , Serruys, Patrick W.

Heart | June 22, 2022 | Volume: 108 | Issue: 22 | Pages: 1784-1791

10.1136/heartjnl-2022-320934 Get It

Objective We sought to investigate whether long-term clinical outcomes differ following percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with three-vessel disease (3VD) and lesions in the proximal left anterior descending artery (P-LAD). Methods This post-hoc analysis of the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) Extended Survival study included patients with 3VD who were classified according to the presence or absence of lesions located in the P-LAD. Ten-year all-cause death and 5-year major adverse cardiac or cerebrovascular events (MACCE) were assessed. Results Among 1088 patients with 3VD, 559 (51.4%) had involvement of P-LAD and their 10-year mortality was numerically higher following PCI versus CABG (28.9% vs 21.9%; HR: 1.39, 95% CI 0.99 to 1.95). Although patients without P-LAD lesions had significantly higher 10-year mortality following PCI compared with CABG, there was no evidence of a treatment-by-subgroup interaction (28.8% vs 20.2%; HR: 1.47, 95% CI 1.03 to 2.09, pinteraction=0.837). The incidence of MACCE at 5 years was significantly higher with PCI than CABG, irrespective of involvement of P-LAD (with P-LAD: HR: 1.86, 95% CI 1.36 to 2.55; without P-LAD: HR: 1.54, 95% CI 1.11 to 2.12; pinteraction=0.408). Individualised assessment using the SYNTAX Score II 2020 established that a quarter of patients with P-LAD lesions had significantly higher mortality with PCI than CABG, whereas in the remaining three-quarters CABG had similar mortality. Conclusions Among patients with 3VD, the presence or absence of a P-LAD lesion was not associated with any treatment effect on long-term outcomes following PCI or CABG. Trial registration number SYNTAXES: NCT03417050; SYNTAX: NCT00114972.
Long-term survival after coronary bypass surgery with multiple versus single arterial grafts
Thuijs, Daniel J.F.M. , Davierwala, Piroze , Milojevic, Milan , Noack, Thilo , Kappetein, A. Pieter , Mohr, Friedrich‐Wilhelm, Morice, Marie‐Claude, Mack, Michael J. , Ståhle, Elisabeth , Verberkmoes, Niels , Holmes, David R. , Head, Stuart J., Investigators, for the SYNTAX Extended Survival, Noack, Thilo , Kappetein, Arie Pieter , Ståhle, L Elisabeth G E , Serruys, Patrick W , Milojevic, Milan , Deo, Salil V. , Serruys, Patrick W. , Investigators, for the SYNTAX Extended Survival

European Journal of Cardio-Thoracic Surgery | August 8, 2021 | Volume: 61 | Issue: 4 | Pages: 925-933

10.1093/ejcts/ezab392 Get It

Abstract OBJECTIVES This study sought to evaluate the long-term differences in survival between multiple arterial grafts (MAG) and single arterial grafts (SAG) in patients who underwent coronary artery bypass grafting (CABG) in the SYNTAX study. METHODS The present analysis included the randomized and registry-treated CABG patients (n = 1509) from the SYNTAX Extended Survival study (SYNTAXES). Patients with only venous (n = 42) or synthetic grafts (n = 1) were excluded. The primary end point was all-cause death at the longest follow-up. Multivariable Cox regression was used to adjust for differences in baseline characteristics. Sensitivity analysis using propensity matching with inverse probability for treatment weights was performed. RESULTS Of the 1466 included patients, 465 (31.7%) received MAG and 1001 (68.3%) SAG. Patients receiving MAG were younger and at lower risk. At the longest follow-up of 12.6 years, all-cause death occurred in 23.6% of MAG and 40.0% of SAG patients [adjusted hazard ratio (HR) 0.74, 95% confidence interval (CI) (0.55–0.98); P = 0.038], which was confirmed by sensitivity analysis. MAG in patients with the three-vessel disease was associated with significant lower unadjusted and adjusted all-cause death at 12.6 years [adjusted HR 0.65, 95% CI (0.44–0.97); P = 0.033]. In contrast, no significance was observed after risk adjustment in patients with the left main disease, with and without diabetes, or among SYNTAX score tertiles. CONCLUSIONS In the present post hoc analysis of all-comers patients from the SYNTAX trial, MAG resulted in markedly lower all-cause death at 12.6-year follow-up compared to a SAG strategy. Hence, this striking long-term survival benefit of MAG over SAG encourages more extensive use of multiple arterial grafting in selected patients with reasonable life expectancy. Trial registration SYNTAXES ClinicalTrials.gov reference: NCT03417050; SYNTAX ClinicalTrials.gov reference: NCT00114972.
Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease
Davierwala, Piroze , Gao, Chao , Thuijs, Daniel J.F.M. , Wang, Rutao , Hara, Hironori , Ono, Masafumi , Noack, Thilo , Garg, Scot , O’Leary, Neil , Milojevic, Milan , Morice, Marie‐Claude, Mack, Michael J. , Geuns, Robert‐Jan van , Holmes, David R. , Onuma, Yoshinobu , Mohr, Friedrich W., Investigators, for the SYNTAX Extended Survival, Kappetein, Arie Pieter , van Geuns, Robert-Jan , Holmes, David R , Gaudino, Mario , Taggart, David P , Serruys, Patrick W , Noack, Thilo , Garg, Scot , Onuma, Yoshinobu , Milojevic, Milan , Kappetein, A. Pieter , Gaudino, Mario , Serruys, Patrick W. , Investigators, for the SYNTAX Extended Survival

European Heart Journal | August 1, 2021 | Volume: 43 | Issue: 13 | Pages: 1334-1344

10.1093/eurheartj/ehab537 Get It

Abstract Aim The aim of this study was to compare long-term all-cause mortality between patients receiving percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) using multiple (MAG) or single arterial grafting (SAG). Methods and results The current study is a post hoc analysis of the SYNTAX Extended Survival Study, which compared PCI with CABG in patients with three-vessel (3VD) and/or left main coronary artery disease (LMCAD) and evaluated survival with ≥10 years of follow-up. The primary endpoint was all-cause mortality at maximum follow-up (median 11.9 years) assessed in the as-treated population. Of the 1743 patients, 901 (51.7%) underwent PCI, 532 (30.5%) received SAG, and 310 (17.8%) had MAG. At maximum follow-up, all-cause death occurred in 305 (33.9%), 175 (32.9%), and 70 (22.6%) patients in the PCI, SAG, and MAG groups, respectively (P < 0.001). Multiple arterial grafting [adjusted hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.49–0.89], but not SAG (adjusted HR 0.83, 95% CI 0.67–1.03), was associated with significantly lower all-cause mortality compared with PCI. In patients with 3VD, both MAG (adjusted HR 0.55, 95% CI 0.37–0.81) and SAG (adjusted HR 0.68, 95% CI 0.50–0.91) were associated with significantly lower mortality than PCI, whereas in LMCAD patients, no significant differences between PCI and MAG (adjusted HR 0.90, 95% CI 0.56–1.46) or SAG (adjusted HR 1.11, 95% CI 0.81–1.53) were observed. In patients with revascularization of all three major myocardial territories, a positive correlation was observed between the number of myocardial territories receiving arterial grafts and survival (P trend = 0.003). Conclusion Our findings suggest that MAG might be the more desirable configuration for CABG to achieve lower long-term all-cause mortality than PCI in patients with 3VD and/or LMCAD. Trial registration Registered on clinicaltrial.gov. SYNTAXES: NCT03417050 (https://clinicaltrials.gov/ct2/show/NCT03417050); SYNTAX: NCT00114972 (https://www.clinicaltrials.gov/ct2/show/NCT00114972).